330 related articles for article (PubMed ID: 30355936)
1. Predictors and Management of Antiplatelet-Related Bleeding Complications for Acute Coronary Syndrome in Chinese Elderly Patients.
Wan J; Wang P; Zhou P; Liu S; Wang D; Kan J; Hou J; Zuo L; Ma S; Yang Y
Cell Physiol Biochem; 2018; 50(3):1164-1177. PubMed ID: 30355936
[TBL] [Abstract][Full Text] [Related]
2. Effect of over-2-year dual antiplatelet therapy on the rate of major adverse cardiac and cerebral events for everolimus-eluting stent implantation: The landmark analysis from Tokyo-MD PCI registry.
Ueshima D; Ashikaga T; Yoshikawa S; Sasaoka T; Hatano Y; Kurihara K; Maejima Y; Isobe M
J Cardiol; 2017 Jun; 69(6):815-822. PubMed ID: 27692568
[TBL] [Abstract][Full Text] [Related]
3. Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs).
Cuisset T; Grosdidier C; Loundou AD; Quilici J; Loosveld M; Camoin L; Pankert M; Beguin S; Lambert M; Morange PE; Bonnet JL; Alessi MC
JACC Cardiovasc Interv; 2013 Aug; 6(8):854-63. PubMed ID: 23968703
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcomes in patients with acute coronary syndromes related to prolonging dual antiplatelet therapy more than 12 months after coronary stenting.
Wimmer NJ; Dufour AB; Cho K; Gagnon DR; Quach L; Ly S; Do JM; Ostrowski S; Michael Gaziano J; Faxon DP; Kinlay S
Catheter Cardiovasc Interv; 2017 Jun; 89(7):1176-1184. PubMed ID: 27860195
[TBL] [Abstract][Full Text] [Related]
5. Long-term effectiveness and safety of triple versus dual antiplatelet therapy after percutaneous coronary intervention for unprotected left main coronary artery disease.
Lee HJ; Yu CW; Hwang HK; Choi RK; Park JS; Li H; Ro YM
Coron Artery Dis; 2013 Nov; 24(7):542-8. PubMed ID: 23994880
[TBL] [Abstract][Full Text] [Related]
6. Dual Antiplatelet Therapy Guided by CYP2C19 Polymorphisms after Implantation of Second-Generation Drug-Eluting Stents for Management of Acute Coronary Syndrome.
Ozawa T; Suda M; Ikegami R; Takano T; Wakasugi T; Yanagawa T; Tanaka K; Ozaki K; Hirono S; Minamino T
Int Heart J; 2018 Jan; 59(1):21-26. PubMed ID: 29279531
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcomes of extending dual antiplatelet therapy after drug-eluting stent implantation for acute coronary syndrome: a large single-center study.
Xu J; Song Y; Gao Z; Jiang P; Liu R; Wang H; Qiao S; Gao R; Yang Y; Xu B; Yuan J
Platelets; 2020 Oct; 31(7):869-876. PubMed ID: 31741412
[TBL] [Abstract][Full Text] [Related]
8. Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation.
Musumeci G; Rossini R; Lettieri C; Capodanno D; Romano M; Rosiello R; Guagliumi G; Valsecchi O; Gavazzi A; Angiolillo DJ
Catheter Cardiovasc Interv; 2012 Sep; 80(3):395-405. PubMed ID: 22109961
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Prolonged Dual Antiplatelet Therapy after Percutaneous Coronary Intervention in Acute Coronary Syndrome Patients.
Han J; Zhang Y; Shi X; Lin B; Zhang Y; Zhang R; Wang Y; Yan J; Lin Y
Glob Heart; 2023; 18(1):11. PubMed ID: 37228657
[TBL] [Abstract][Full Text] [Related]
10. Analysis of individualized antiplatelet therapy for patients of acute coronary syndrome after percutaneous coronary intervention under the guidance of platelet function: A one-center retrospective cohort study.
Dang W; Wang J; Zhang Q; Liu N; Li W; Yao Z
Medicine (Baltimore); 2021 Apr; 100(16):e25601. PubMed ID: 33879725
[TBL] [Abstract][Full Text] [Related]
11. Predictors and consequences of postdischarge gastrointestinal bleeding after percutaneous coronary intervention.
Zhu P; Tang X; Xu J; Song Y; Liu R; Zhang Y; Gao L; Gao Z; Chen J; Yang Y; Gao R; Xu B; Yuan J
Cardiovasc Ther; 2018 Oct; 36(5):e12440. PubMed ID: 29863803
[TBL] [Abstract][Full Text] [Related]
12. The PRECISE-DAPT score and 5-year outcomes after percutaneous coronary intervention: a large-scale, real-world study from China.
Zhao X; Li J; Liu F; Zhu P; Jiang L; Tang X; Xu J; Song Y; Chen J; Qiao S; Yang Y; Gao R; Xu B; Han Y; Yuan J
Eur Heart J Qual Care Clin Outcomes; 2022 Nov; 8(8):812-820. PubMed ID: 34558620
[TBL] [Abstract][Full Text] [Related]
13. Age and outcomes following personalized antiplatelet therapy in chronic coronary syndrome patients: a post hoc analysis of the randomized PATH-PCI trial.
Pan Y; Wu TT; Hou XG; Yang Y; Deng CJ; Wang S; Zheng YY; Xie X
Platelets; 2023 Dec; 34(1):2206915. PubMed ID: 37154019
[TBL] [Abstract][Full Text] [Related]
14. Impact of Sex on 2-Year Clinical Outcomes in Patients Treated With 6-Month or 24-Month Dual-Antiplatelet Therapy Duration: A Pre-Specified Analysis From the PRODIGY Trial.
Gargiulo G; Ariotti S; Santucci A; Piccolo R; Baldo A; Franzone A; Magnani G; Marino M; Esposito G; Windecker S; Valgimigli M
JACC Cardiovasc Interv; 2016 Sep; 9(17):1780-9. PubMed ID: 27544007
[TBL] [Abstract][Full Text] [Related]
15. Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention With Stents.
Yu J; Baber U; Mastoris I; Dangas G; Sartori S; Steg PG; Cohen DJ; Giustino G; Chandrasekhar J; Ariti C; Witzenbichler B; Henry TD; Kini AS; Krucoff MW; Gibson CM; Chieffo A; Moliterno DJ; Colombo A; Pocock S; Mehran R
JACC Cardiovasc Interv; 2016 Jul; 9(14):1461-9. PubMed ID: 27478113
[TBL] [Abstract][Full Text] [Related]
16. Prevalence, Management, and Long-Term (6-Year) Outcomes of Atrial Fibrillation Among Patients Receiving Drug-Eluting Coronary Stents.
Choi HI; Ahn JM; Kang SH; Lee PH; Kang SJ; Lee SW; Kim YH; Lee CW; Park SW; Park DW; Park SJ
JACC Cardiovasc Interv; 2017 Jun; 10(11):1075-1085. PubMed ID: 28527773
[TBL] [Abstract][Full Text] [Related]
17. Dual antiplatelet therapy in patients with a long coronary artery lesion over 30 mm: Determinants and impact on prognosis.
Manchuelle A; Delhaye C; Schurtz G; Sudre A; Hurt C; Bonello L; Puymirat E; Bauters C; Lemesle G
Arch Cardiovasc Dis; 2015 Apr; 108(4):235-43. PubMed ID: 25682548
[TBL] [Abstract][Full Text] [Related]
18. Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting.
Costa F; Van Klaveren D; Feres F; James S; Räber L; Pilgrim T; Hong MK; Kim HS; Colombo A; Steg PG; Bhatt DL; Stone GW; Windecker S; Steyerberg EW; Valgimigli M;
J Am Coll Cardiol; 2019 Feb; 73(7):741-754. PubMed ID: 30784667
[TBL] [Abstract][Full Text] [Related]
19. Sex-Related Bleeding Risk in Acute Coronary Syndrome Patients Receiving Dual Antiplatelet Therapy with Aspirin and a P2Y12 Inhibitor.
Ten Haaf ME; van Geuns RJ; van der Linden MMJM; Smits PC; de Vries AG; Doevendans PA; Appelman Y; Boersma E
Med Princ Pract; 2023; 32(3):200-208. PubMed ID: 36948164
[TBL] [Abstract][Full Text] [Related]
20. Duration of clopidogrel-based dual antiplatelet therapy and clinical outcomes after endeavor sprint zotarolimus-eluting stent implantation in patients presenting with acute coronary syndrome.
Song PS; Hahn JY; Kim DI; Song YB; Choi SH; Choi JH; Ryu DR; Hur SH; Jeong JO; Park HS; Kim HS; Gwon HC
Eur J Intern Med; 2015 Sep; 26(7):521-7. PubMed ID: 26153337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
